Analyst Profile

Followed by 74 followers
.
Daina Graybosch

Daina Graybosch

SVB Securities
Wall Street Analyst
#8,010 out of 8,087 Wall Street Analysts
#23,889 out of 24,283 experts

Success Rate

30%
53 out of 174 transactions made a profit

Average Return

-18.30%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
Copying Daina Graybosch's trades since 2019 and holding each position for 1 Year would result in 30.46% of your transactions generating a profit, with an average return of -18.3% per rating.

Stock Rating Distribution

264Ratings
79.92% Buy
20.08% Hold
0.00% Sell
Distribution of Daina Graybosch's ratings

Additional Information

Main Sector:General
Geo Coverage:
United StatesUS Market
United KingdomUK Market

Best Rating

Stock:
Fate Therapeutics Inc
(FATE)
Rating:Buy
Date:Mar 12, 2020 - Mar 12, 2021
Return:+370.10%
The most profitable rating made by Daina Graybosch

Daina Graybosch's Stock Coverage

Company
Date
Position
Action
Price Target
No. of Ratings
Success Rate
Avg. Return
Chinook Therapeutics
Apr 15, 2019
Buy
Initiated
$9.00
(-61.77% Downside)
1Ratings
0%
-9.90%
Forte Biosciences
May 22, 2019
Hold
Reiterated
$5.00
(402.41% Upside)
1Ratings
0.00%
THOR
Synthorx
Dec 11, 2019
Hold
Downgraded
1Ratings
0.00%
Merck KGaA
Aug 25, 2020
Buy
Reiterated
€95.49
(-44.91% Downside)
3Ratings
100%
+46.47%
Molecular Partners AG
Apr 06, 2021
Buy
Reiterated
$37.15
(451.24% Upside)
1Ratings
0%
-18.60%
ARS Pharmaceuticals
Apr 01, 2022
Hold
Downgraded
$1.80
(-75.48% Downside)
8Ratings
0%
-79.46%
Genocea Biosciences
Apr 27, 2022
Buy
Reiterated
$5.00
(72363.77% Upside)
10Ratings
11%
-54.43%
Werewolf Therapeutics
May 10, 2022
Buy
Reiterated
$17.00
(1011.11% Upside)
6Ratings
0%
-67.03%
F-star Therapeutics
Jun 23, 2022
Hold
Downgraded
$7.00
(34.62% Upside)
7Ratings
67%
+47.25%
BioNTech SE
Jul 29, 2022
Buy
Assigned
$224.00
(37.74% Upside)
24Ratings
100%
+42.25%
List of latest recommendations made by Daina Graybosch. Click to expand and see Daina Graybosch's performance on a particular stock
Disclaimer: TipRanks collects analysts’ ratings and price targets by scanning publicly available reports on financial websites and by receiving reports from analysts, firms, or customers. The information and statistics displayed might not be accurate, complete, or up-to-date. The analyst ratings provided are the sole responsibility of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings, or opinions expressed.
Send Us Reports
If you receive reports that you think we are missing, we will thank you with a free Ultimate upgrade!
Learn More >